🤖 Search 5,000+ AI tools Ask our bot for help →

Discover the latest tools and trends in AI 🔮

Join 60,000+ subscribers including Amazon, Apple, Google, and Microsoft employees reading our free newsletter.

[email protected] Subscribe

LabGenius bags £35M Series B for biotech expansion

LabGenius bags £35M Series B for biotech expansion
LabGenius bags £35M Series B for biotech expansion

LabGenius, a London-based drug discovery firm, secured £35M in Series B funding.

The round was led by M Ventures, with participation from Octopus Ventures, LG Corp, and existing backers like Atomico and Lux Capital.

The funds will enhance LabGenius' ML-driven drug discovery platform and push its multispecific antibodies pipeline for solid tumors towards clinical trials.

LabGenius, spearheaded by CEO Dr. James Field, pioneers next-gen therapeutic antibody discovery through its EVA™ platform, blending AI, robotic automation, and synthetic biology.

Comments